- Home
- SGMT vs CODA Comparison
SGMT vs CODA Comparison
Compare SGMT & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGMT | CODA |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | United States | United States |
| Employees | N/A | 100 |
| Industry | | Industrial Machinery/Components |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.6M | 155.4M |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | SGMT | CODA |
|---|---|---|
| Price | $5.74 | $14.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $27.00 | N/A |
| AVG Volume (30 Days) | ★ 566.6K | 203.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.49 | 15.62 |
| EPS | N/A | ★ 0.37 |
| Revenue | $2,000,000.00 | ★ $20,316,161.00 |
| Revenue This Year | N/A | $16.42 |
| Revenue Next Year | N/A | $14.43 |
| P/E Ratio | ★ N/A | $36.89 |
| Revenue Growth | N/A | ★ 4.98 |
| 52 Week Low | $1.73 | $5.76 |
| 52 Week High | $11.41 | $14.89 |
Technical Indicators
Market Signals| Indicator | SGMT | CODA |
|---|---|---|
| Relative Strength Index (RSI) | 51.03 | 61.25 |
| Support Level | $5.60 | $7.47 |
| Resistance Level | $6.72 | N/A |
| Average True Range (ATR) | 0.33 | 0.87 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 62.78 | 79.29 |
Price Performance
Historical ComparisonAbout SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.